FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy

Table 3 Determination of SUV_max cut-offs for pathological T-stage

T-stage	SUV_max cut-off	AUROC curve	95% confidence interval
CRT ^[−] group
T ≥ T1	1.9	1.00^a	0.92 ~ 1.00
T ≥ T2	4.4	0.88^a	0.75 ~ 0.96
T ≥ T3	6.5	0.95^a	0.84 ~ 0.99
T : T4	13.0	N/A^b	N/A
CRT ^[+] group
T ≥ T1	3.4	0.89^a	0.77 ~ 0.95
T ≥ T2	3.9	0.93^a	0.83 ~ 0.98
T ≥ T3	5.5	0.95^a	0.85 ~ 0.99
T : T4	6.2	0.95^a	0.86 ~ 0.99

^a p < 0.05
^bData unavailable because there was only one patient with a T4 tumor in the CRT^[−] group
AUROC area under the receiver-operating-characteristic, CRT chemoradiotherapy, SUV _max maximal standardized uptake value

ISSN: 1471-2342